Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Trinidad & Tobago Wellness Today.
Press releases published on September 8, 2025
Harrow Announces Pricing of $250.0 Million Offering of Senior Unsecured Notes Due 2030
NASHVILLE, Tenn., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the pricing of its private offering (the “Offering”) of $250.0 million aggregate …
NurExone Receives U.S. Patent Allowance for Exosome Manufacturing, Strengthening Supply Chain Readiness
TORONTO and HAIFA, Israel, Sept. 08, 2025 (GLOBE NEWSWIRE) -- NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company”), a pioneering biopharmaceutical company developing exosome-based regenerative therapies, is pleased to …
Onco360® Has Been Selected as a National Specialty Pharmacy Partner for Wayrilz™ (rilzabrutinib)
LOUISVILLE, Ky., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Onco360®, the nation’s leading independent specialty pharmacy, has been selected as a pharmacy partner by Sanofi for Wayrilz (rilzabrutinib), which has been approved by the U.S. Food and Drug …
PharmAla Completes Import of LaNeo MDMA for US Distribution
TORONTO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC:MDXXF), a biotechnology company focused on the research, development, and manufacturing of novel MDXX class molecules (including its …
Immix Biopharma Announces Strategic Investment by Houston based Goose Capital, led by founding member Dr. Nancy T. Chang
LOS ANGELES, CA, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Immix Biopharma, Inc. (“Immix”, “Company”, “We” or “Us” or ”IMMX”), a clinical-stage biopharmaceutical company developing cell therapies for AL Amyloidosis and other serious diseases, today announced that …
Enovis Corporation Announces Time Change for Presentation at Baird 2025 Global Healthcare Conference
Wilmington, DE, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Enovis™ Corporation (NYSE: ENOV), an innovation-driven, medical technology growth company, today announced that it will now present at the Baird 2025 Global Healthcare Conference at 2:35 p.m. ET on …
Rapport Announces Proposed Public Offering of Common Stock
BOSTON and SAN DIEGO, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Rapport Therapeutics, Inc. (Nasdaq: RAPP) (“Rapport” or the “Company”), a clinical-stage biotechnology company dedicated to the discovery and development of small molecule precision medicines for …
Dianthus Therapeutics, Inc. Announces Proposed $150 Million Underwritten Public Offering
NEW YORK and WALTHAM, Mass., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Dianthus Therapeutics, Inc. (Nasdaq: DNTH), a clinical-stage biotechnology company dedicated to advancing the next generation of antibody complement therapeutics to treat severe autoimmune …
Nora Mental Health Opens New Location in Dallas, TX, Bringing Compassionate, Accessible Mental Health Care to the Community
Dallas, TX , Sept. 08, 2025 (GLOBE NEWSWIRE) -- Nora Mental Health is excited to announce the grand opening of its newest clinic in Dallas, Texas, located at 8140 Walnut Hill Ln, Suite 835. The new location reflects the growing demand for accessible, high- …
Claisen Launches Direct-to-Consumer Personalized Kits for Gastrointestinal Diseases (Heartburn, Bloating, and Gas)
BOSTON, MA, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Claisen Inc., a telemedicine and digital gastrointestinal health company, today announced the launch of personalised, direct-to-consumer gut health kits that help patients manage acid reflux/GERD, bloating, …
Beyond Air Announces Exercise of Warrants for $3.25 Million of Gross Proceeds
GARDEN CITY, N.Y., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Beyond Air, Inc. (NASDAQ: XAIR) (“Beyond Air” or the “Company”), a commercial stage medical device and biopharmaceutical company focused on harnessing the power of nitric oxide (NO) to improve the lives …
Tren Cycle for Bodybuilding: CrazyBulk Introduce Test and Tren Stack for Muscle Growth, Dosage, Benefits & Results
New York City, NY, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Introduction: The Ultimate Tren Cycle and Why the Tren and Test Conversation Dominates Modern Bodybuilding Tren and Test dominate the narrative of contemporary bodybuilding. It delivers striking gains …
Most Popular Legal Steroids for Muscle Building from CrazyBulk: Best Selling Steroid Alternatives for Muscle Growth and Cutting in 2025
New York City, NY, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Introduction: What are the best legal steroid alternatives for muscle growth and fat loss from Crazybulk’s supplement range. In 2025, demand for legal steroid substitutes is steadily rising as …
Shiny Smile Veneers Surpasses 100,000 Smiles Transformed in 2025 as Demand for Lifestyle Dental Health Solutions Grows
Providence, Sept. 08, 2025 (GLOBE NEWSWIRE) -- Disclaimer: This press release is for informational purposes only. The information contained herein does not constitute dental advice, diagnosis, or treatment and has not been evaluated by the Food and Drug …
WellSpan ACO earns high performance, savings under Medicare Shared Savings Program
York, Pa., Sept. 08, 2025 (GLOBE NEWSWIRE) -- The Centers for Medicare and Medicaid Services (CMS) has once again acknowledged WellSpan Health's commitment to making health care more affordable, noting that the organization in 2024 saved patients, partners …
DPP1 Inhibitor Market Set to Reach New Heights in the Coming Decade | DelveInsight
New York, USA, Sept. 08, 2025 (GLOBE NEWSWIRE) -- DPP1 Inhibitor Market Set to Reach New Heights in the Coming Decade | DelveInsight The DPP1 inhibitor market is experiencing significant growth, driven by the recent BRINSUPRI approval for non-cystic …
Press Release : Sequana Medical Announces New Share Capital Amount and New Number of Shares
SEQUANA MEDICAL ANNOUNCES NEW SHARE CAPITAL AMOUNT AND NEW NUMBER OF SHARES Ghent, Belgium, 8 September 2025 – Sequana Medical NV (Euronext Brussels: SEQUA) (the "Company" or "Sequana Medical"), a pioneer in the treatment of drug-resistant fluid overload …
OSE Immunotherapeutics Provides Update on Ongoing Proceedings Ahead of Shareholders’ Annual General Meeting of September 30, 2025
OSE Immunotherapeutics Provides Update on Ongoing Proceedings Ahead of Shareholders’ Annual General Meeting of September 30, 2025 NANTES, France, September 8, 2025, 6p.m. CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) announces that, …
OSE Immunotherapeutics fait le point sur les procédures en cours avant l’Assemblée Générale Annuelle des actionnaires du 30 septembre 2025
OSE Immunotherapeutics fait le point sur les procédures en cours avant l’Assemblée Générale Annuelle des actionnaires du 30 septembre 2025 NANTES, France – 8 septembre 2025, 18 heures – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) annonce qu’ …
Idorsia highlights very low real-world abuse potential of DORA class for insomnia treatment at WSC 2025
Analysis of the FAERS database shows that the real-world abuse potential of the DORA class is very low and markedly less than those seen for other scheduled and non-scheduled insomnia therapies Allschwil, Switzerland – September 8, 2025 Idorsia Ltd (SIX: …